Background: Individuals with Barrett's esophagus, in which the normal squamous esophageal epithelium is replaced with a columnar mucosa, are at increased risk for esophageal adenocarcinoma. Mucosal injury may be involved in the progression to neoplasia via the synthesis of prostaglandins and other mediators of inflammation. Cyclooxygenase (COX)-2 is the rate-limiting enzyme involved in prostaglandin synthesis. We examined the effect of inhibiting COX-2 activity in Barrett's esophageal cells. Methods: Primary esophageal epithelial and fibroblast cell cultures were established from endoscopic biopsy specimens from 20 consecutive patients with Barrett's esophagus. COX-2 expression and activity were determined on pooled cell cultures by reverse transcription-polymerase chain reaction and prostaglandin E 2 (PGE 2 ) enzyme immunoassay, respectively. Proliferation was measured by Ki-67 staining. PGE 2 levels were determined in supernatants from epithelial cells treated with the selective COX-2 inhibitor NS-398, proinflammatory cytokines (interleukin 1␤ and tumor necrosis factor-␣), and conditioned medium from fibroblast cultures (both unstimulated and stimulated with proinflammatory cytokines). 
Barrett's esophagus is a complication of chronic gastroesophageal reflux disease and is characterized by the replacement of the normal squamous esophageal epithelium with a specialized columnar mucosa. It is associated with an increased risk of esophageal adenocarcinoma, which has been the most rapidly increasing cancer in Caucasian males in the United States over the last three decades (1-3) . The etiopathogenesis of Barrett's esophagus and its progression to cancer are not well understood. It has been proposed that reflux of gastric acid and bile into the esophagus can cause injury to the esophageal mucosa and that sustained injury may play a role in the development and progression of neoplasia in Barrett's esophagus (4, 5) . This injury may induce the synthesis and release of soluble mediators of inflammation, including prostaglandins and proinflammatory cytokines.
The rate-limiting step in the synthesis of prostaglandins is the conversion of arachidonic acid to prostaglandin. The enzyme that controls this crucial step is cyclooxygenase (COX), of which there are two isoforms, COX-1 and COX-2. The isoforms are regulated by different mechanisms and have different patterns of expression. Expression of COX-1 is predominantly constitutive, whereas expression of COX-2 is inducible by mediators of inflammation, such as proinflammatory cytokines including interleukin (IL)-1␤ and tumor necrosis factor (TNF)-␣ (6) (7) (8) (9) . Regulation of COX activity and prostaglandins has been shown to be important in the development of colon cancers (10, 11) , in which it is thought that prostaglandins can alter cell turnover and immune responses (12, 13) . Although expression of COX-2 messenger RNA (mRNA) and protein increases with the various stages of neoplasia that develop in Barrett's esophagus (14) , whether COX-2 expression in Barrett's esophagus has any functional role in the progression to neoplasia has not been demonstrated.
The expression of COX-2 is restricted to the stroma of the esophagus during the early stages of neoplasia in Barrett's esophagus (14) . There is evidence that mesenchymal-epithelial interactions are important in the development of gastrointestinal neoplasia, although this has not been directly examined in Barrett's esophagus (15) . The mesenchymal-epithelial interactions may occur through direct cell-cell contacts or indirectly, through the release of soluble mediators, such as prostaglandins and proinflammatory cytokines. Gastroesophageal reflux is associated with increased proinflammatory cytokine activity (such as IL-1) in the esophagus (16) , but the effect of these proinflammatory cytokine mediators on COX-2 activity of Barrett's esophageal epithelial cells and the modulation of COX-2 activity of Barrett's esophageal epithelial cells by stromal cells remain undefined.
In this study, we examined the expression of COX-2 in Barrett's esophageal epithelial cells and esophageal fibroblasts and assessed the relative COX-2 activity of these cells in the presence of proinflammatory cytokines. We also evaluated the effect of a selective COX-2 inhibitor, NS-398, on the proliferation of Barrett's esophageal epithelial cells to determine its chemopreventive potential.
MATERIALS AND METHODS

Biopsy Specimens
The Institutional Review Board of the Mayo Graduate School of Medicine (Rochester, MN) approved the study, and all patients provided written informed consent to provide tissue. Tissue samples were obtained during routine surveillance endoscopy performed between August 1999 and February 2000 on 20 consecutive patients who were known to have Barrett's esophagus. Barrett's esophagus is defined by the presence of specialized columnar metaplasia on biopsy specimens from the esophagus. Four biopsy specimens from each patient were taken for cell culture. Additional biopsy specimens from the Barrett's segment were obtained for histologic analyses by taking four quadrant biopsies in every centimeter of Barrett's mucosa. Eighteen of the 20 patients were male, with a mean age of 65 ± 9 years (mean ± SD). Ten patients had Barrett's esophagus without dysplasia, five had low-grade dysplasia, and five had high-grade dysplasia.
Cell Culture
Barrett's esophageal epithelial and fibroblast primary cultures. Biopsy specimens for tissue culture were immediately placed on ice in minimal essential medium (Sigma Chemical Co., St. Louis, MO). Within 4 hours from the time of the biopsy, the specimens were minced into approximately 2-mm 3 fragments. Primary cell cultures were initiated by maintaining the cells in Barrett's plus media, as previously described (17), containing 5% fetal bovine serum (FBS), 0.4 g/mL hydrocortisone (Sigma Chemical Co.), 20 ng/mL epidermal growth factor (GIBCO BRL, Grand Island, NY), 10 -10 mol/L cholera toxin (Sigma Chemical Co.), 140 g/mL bovine pituitary extract (Sigma Chemical Co.), 20 g/mL adenine (Sigma Chemical Co.), 100 U/mL penicillin (GIBCO BRL), 100 g/mL streptomycin (GIBCO BRL), 0.25 g/mL amphotericin B (GIBCO BRL), 4 mmol/L glutamine (GIBCO BRL), 5 g/mL insulin, 5 g/mL transferrin, and 5 ng/mL selenium (Sigma Chemical Co.). Cells were maintained in a humidified atmosphere containing 5% CO 2 in air at 37°C. Esophageal fibroblast cultures from the biopsy specimens were isolated by allowing the fibroblasts to overgrow the epithelial cell culture for 4-6 weeks. After differential trypsinization (17) , the fibroblast cultures were maintained in Dulbecco's modified Eagle medium (DMEM; Sigma Chemical Co.) with 10% FBS. Epithelial cells and fibroblasts were detached with trypsin, and aliquots of the cell suspensions (30 000 cells/mL) were placed in each well of four-well chamber slides for 72 hours. Because only a limited number of epithelial cells could be grown as a primary culture from a single patient, experiments used cells pooled from several patients. Cells were pooled from consecutive patients without selection or segregation. For any given experiment, pooled cultured cells were obtained from two or three patients. Cell cultures derived from both dysplastic and nondysplastic tissues were combined.
Cultures of Barrett's esophageal epithelial cells were characterized by direct light microscopy after cytochemical staining with hematoxylin and eosin, periodic acid-Schiff, and Alcian blue (pH 2.5) and immunostaining with a panel of monoclonal anti-keratin antibodies (KA4, KA5, and RGE53) as previously described (18 
Analysis of COX-2 Expression and Activity
COX-2 mRNA expression was assessed by reverse transcription-polymerase chain reaction (PCR). Total cellular RNA was extracted from the Barrett's esophageal epithelial cell and fibroblast cultures and from the HCA-7 and HCT-15 cell lines with the RNeasy Extraction Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Reverse transcription-PCR was performed using the Qiagen One Step Kit (Qiagen). A master mix of enzymes and buffers was made and, after the addition of the COX-2 primers (5Ј-TGAAACCCACTCCAAACACAG-3Ј, and 5Ј-TCATCAGGCACAGGAGGAAG-3Ј) (20) , 50-L aliquots of the mix were placed in individual PCR tubes along with 1 g of the extracted RNA from each sample. The tubes then were placed in a PerkinElmer Gene Amp 9600 system thermocycler and heated to 50°C for 30 minutes. Subsequently, the tubes were heated to 95°C for 15 minutes to inactivate the reverse transcriptase and activate the HotStarTaq polymerase, which began the PCR cycles (21) of 94°C for 60 seconds, 52°C for 60 seconds, and then 72°C for 60 seconds. Finally, after 40 PCR cycles, the tubes were heated to 72°C for 10 minutes and cooled to 4°C overnight. ␤-Globin primers were used as internal controls for loading the RNA (22) . PCR products were separated by electrophoresis through 1.2% agarose gels and visualized after staining the gels with 0.5 g/mL ethidium bromide. The size of PCR products was assessed by comparing the PCR products with 2 g of HaeIII-digested 174 marker (GIBCO BRL) that was subjected to electrophoresis through the same gel. The predicted sizes of the PCR products were 232 bp for COX-2 and 600 bp for ␤-globin.
Analysis of COX-2 activity. COX-2 activity was assessed in cell culture supernatants with the use of a competitive PGE 2 enzyme immunoassay kit (Cayman Chemical Co., Ann Arbor, MI) according to the manufacturer's recommendations. Duplicates of known PGE 2 concentrations were used to generate a standard curve from which the PGE 2 concentrations in the supernatants could be determined. Intra-and interassay coefficient of variance was less than 10%. The specificity of the assay is 100% for PGE 2 , with a minimal detection limit of 75 pg/mL.
Final PGE 2 concentrations were converted on a log scale and corrected for the level of protein content of the cell culture; this minimized the effect of any differences in cell number. The total protein concentration of the cell cultures was determined with the use of a Micro BCA protein assay kit (Pierce, Rockford, IL). For some experiments, cell cultures were treated for 24 h with a combination of the cytokines IL-1␤ (final concentration 10 ng/ mL) and TNF-␣ (final concentration 50 ng/mL) before the PGE 2 concentration was measured in the culture supernatants.
Analysis of Cell Proliferation and Apoptosis
The 72-h, four-well cultures of Barrett's esophageal epithelial cells, HCA-7, and HCT-15 were treated with 1, 25, and 50 mol of the selective COX-2 inhibitor, NS-398 (Cayman Chemical Co.) or treated with an equivalent volume of the diluent dimethyl sulfoxide (DMSO; final concentration 0.1%). The culture media containing the drug or the diluent were replaced every other day for 6 days. Proliferation was assessed by immunostaining the cells with the Ki-67 mouse monoclonal antibody, which detects the nuclei of proliferating cells (Roche Diagnostics, Indianapolis, IN). After the supernatant was removed, the cells on the four-well chamber slides were rinsed three times with phosphate-buffered saline (PBS) at pH 7.4 and air-dried. Slides were stored at 4°C until stained. Immediately before staining, cells were fixed in ice-cold methanol for 30 minutes. Slides were washed twice with PBT (PBS containing 0.1% bovine serum albumin and 1% Tween 20, made with Sigma reagents). After several washes, slides were incubated with the Ki-67 antibody (10 g/mL) in PBT at room temperature for 30 minutes. Slides were washed twice with PBT and then incubated with fluorescein-conjugated anti-mouse immunoglobulin G (Roche Diagnostics) (10 g/mL) in PBS for 30 minutes at room temperature, in the dark. After washing twice with PBS, coverslips were applied to the slides with GEL/Mount (Biomedia Corp., Foster City, CA) and stored at 4°C in the dark until read. The total number of Ki-67-positive cells, which reflects the number of potentially proliferating cells, was determined in each sample by directly counting the cells on a fluorescence microscope (Axiophot; Carl Zeiss, New York, NY). A minimum of 300 cells was scored for every treatment, and each sample was counted twice by the same technician. A four-well chamber control slide with the immortal keratinocyte HaCats cell line was included with each batch as an internal control for staining. HaCats cells were treated with or without cyclohexamide (100 g/mL). Cyclohexamide-treated cells do not proliferate and were used as a negative internal control for the Ki-67 staining.
In a separate experiment, to overcome the effect of inhibiting COX-2 activity on the proliferation of Barrett's esophageal epithelial cells, the 72-h, four-well cell cultures were treated with exogenous PGE 2 (1 ng/mL), with PGE 2 (1 ng/mL) and NS-398 (50 mol), or with NS-398 (50 mol) for 48 hours. For a control, Barrett's esophageal epithelial cells were treated with DMSO (final concentration 0.1%).
Analysis of Apoptosis
The terminal deoxynucleotidyltransferase-mediated uridine triphosphate nick end-labeling assay (TUNEL assay; Roche Diagnostics) was used to determine whether inhibition of COX-2 activity induced apoptosis. The 72-h, four-well cultures of Barrett's esophageal epithelial cells were treated with 1, 25, and 50 mol of the selective COX-2 inhibitor, NS-398 (Cayman Chemical Co.) or treated with an equivalent volume of the diluent DMSO (final concentration 0.1%). The culture media containing the drug or the diluent were replaced every other day for 6 days. Apoptosis was assessed at the end of the experiment. After removal of the supernatant, the Barrett's esophageal epithelial cells were incubated in a solution of 0.1% Triton X-100, 0.1% sodium citrate for 2 minutes on ice (4°C). After this permeabilization step, 50 L of the TUNEL reaction mixture was added to the cells. The cells then were incubated in a humidified chamber for 60 min at 37°C in the dark. The same technician analyzed all samples under a fluorescence microscope and recorded the percentage of cells undergoing apoptosis. A four-well chamber control slide with HaCats cells was included as an internal control for staining. HaCats cells were treated with 100 g/mL cyclohexamide to induce apoptosis (positive control) or DMSO (final concentration 0.1%). A well stained without the TUNEL mixture served as a negative control.
Preparation of Esophageal Fibroblast-Conditioned Medium and Testing Its Effect on COX-2 Activity
Fibroblasts were grown to a culture confluence of 75%-90%, rinsed twice with serum-free DMEM, and grown in a serum-free modification of Barrett's plus media (SFD) containing bovine pituitary extract (140 g/mL) and bovine serum albumin (0.1%). For the last 24 h of a 72-h incubation, a combination of IL-1␤ (10 ng/mL) and TNF-␣ (50 ng/mL) was added to the culture medium. After incubation, the supernatants were removed, centrifuged at 800g in a bench top centrifuge for 15 minutes at room temperature, passed through a 0.2-m filter, and then stored at -20°C.
To test the effect of esophageal fibroblasts on Barrett's esophageal epithelial cell COX-2 activity, the culture medium from the 72-h, four-well Barrett's esophageal epithelial cell cultures was removed and replaced with either 1 mL of SFD medium, SFD medium containing a combination of IL-1␤ (10 ng/ mL) and TNF-␣ (50 ng/mL), or conditioned medium obtained from unstimulated or IL-1␤-stimulated and TNF-␣-stimulated fibroblasts. Because of the limited amount of Barrett's esophageal epithelial cells and fibroblasts available, the combination of the proinflammatory cytokines IL-1␤ and TNF-␣ was used to maximally induce COX-2 activity (7) (8) (9) . Control cells were treated with SFD medium alone or conditioned medium obtained from an unstimulated fibroblast culture. After 24 h, PGE 2 levels were measured in the supernatants of the Barrett's esophageal epithelial cell cultures to determine COX-2 activity.
Statistical Analysis
Results are expressed as means with 95% confidence intervals (95% CIs). Each experiment was repeated at least four times. Cell proliferation and apoptosis are shown as the percentage of cells proliferating or undergoing apoptosis from a total of at least 300 cells. The COX-2 activity was expressed as a PGE 2 level in nanograms per milligram of protein in the supernatant of cell cultures.
To provide approximate normality for modeling purposes, when the response variable was a proportion, we used the arcsine transformation. The transformed value is equal to the arcsine of the square root of the proportion. A log transformation was used for experiments in which the variable was the prostaglandin level. Repeated-measures models with a compound symmetric covariance structure, that is, equal correlation be-tween all pairs of treatments, were fit. These models were used because every time the experiment was repeated all the treatments were given. An overall F-test of treatment mean equality was done using each model. When the overall test was statistically significant at the ␣ ‫ס‬ 0.05 level, we compared the treatment means in a pairwise fashion using the Bonferroni method of multiple comparisons (t tests). Statistical analysis was performed using SAS software (version 6.12; SAS Institute, Cary, NC). All statistical tests were two-sided.
RESULTS
Cell Culture
In culture, Barrett's esophageal epithelial cells were polygonal and spread in a monolayer. More than 90% of the cells were positive for periodic acid-Schiff, Alcian blue (pH 2.5), by cytochemical staining; positive for a panel of keratin proteins detected with mouse monoclonal antibodies (KA4, KA5, and RGE53); and positive for a Barrett's esophagus-specific antigen detected with the monoclonal antibody Mab-Das-1. Less than 10% of the cells were fusiform or polygonal, positive for vimentin, and variably positive for ␣-smooth muscle actin, but negative for the epithelial markers above. Esophageal fibroblast cultures were more than 90% fusiform cells. These cells were negative for periodic acid-Schiff, Alcian blue (pH 2.5), KA4, KA5, RGE53, and Mab-Das-1 staining but were positive for vimentin and variably positive for ␣-smooth muscle actin. The morphologic and cytochemical characteristics of the cultures are similar to the Barrett's esophageal epithelial and fibroblast cultures previously reported (17) (18) (19) .
COX-2 Expression and COX-2 Activity of Barrett's Esophageal Epithelial Cells and Fibroblasts
Both Barrett's esophageal epithelial and esophageal fibroblast primary cell cultures expressed COX-2 mRNA by reverse transcription-PCR (Fig.1, A) . The steady-state COX-2 mRNA levels were comparable after culture in either the presence or absence of the proinflammatory cytokines IL-1␤ (10 ng/mL) and TNF-␣ (50 ng/mL) for 24 hours (Fig. 1, A) . Cells for this experiment were pooled from two patients: one with dysplastic esophageal epithelium and one with nondysplastic esophageal epithelium.
Because PGE 2 levels are directly dependent on COX-2 activity, quantitative measurements of PGE 2 can be used to assess relative COX-2 activity. The PGE 2 level in epithelial cell culture supernatants was 0.2 ng/mg protein (95% CI ‫ס‬ 0 to 1.2), which was statistically significantly different from the 2 ng/mg protein (95% CI ‫ס‬ 1.0 to 3.1) from fibroblasts (P ‫ס‬ .002). Treatment of Barrett's esophageal epithelial cells with IL-1␤ and TNF-␣ increased the PGE 2 level in culture supernatants from 0.2 ng/mg protein (95% CI ‫ס‬ 0 to 1.2) to 0.9 ng/mg protein (95% CI ‫ס‬ 0 to 2.3), a statistically nonsignificant difference (P ‫ס‬ .044, Bonferroni adjusted ␣ ‫ס‬ 0.005). However, IL-1␤ and TNF-␣ treatment of esophageal fibroblasts statistically significantly increased the PGE 2 level from 2 ng/mg protein (95% CI ‫ס‬ 1 to 3.1) to 2.9 ng/mg protein (95% CI ‫ס‬ 1.9 to 3.9) (P<.001, Bonferroni adjusted ␣ ‫ס‬ 0.005) (Fig. 1, B) . COX-2 activity (i.e., PGE 2 levels) was also statistically significantly higher in the culture supernatants of IL-1␤-treated and TNF-␣-treated fibroblasts than in those of IL-1␤-treated and TNF-␣-treated Barrett's esophageal epithelial cells (P<.001, Bonferroni adjusted ␣ ‫ס‬ 0.005). The COX-2-expressing HCA-7 colon cancer cell line, which served as a positive control, expressed COX-2 mRNA and produced high PGE 2 levels of 3.4 ng/mg protein (95% CI ‫ס‬ 2.4 to 4.4), whereas the COX-2-deficient HCT-15 colon cancer cell line, which served as a negative control, did not express COX-2 mRNA and had undetectable levels of PGE 2 .
Proliferation, Apoptosis, and COX-2 Inhibition
To determine a functional role for COX-2 activity in Barrett's esophageal epithelial cells, we assessed cell proliferation in the presence of a selective COX-2 inhibitor (NS-398). A 6-day treat-
Fig. 1. Cyclooxygenase (COX)-2 expression and activity in various cell lines. A)
Total RNA was extracted from pooled primary Barrett's esophageal epithelial cell cultures (BECC), primary esophageal fibroblast cultures (BSFC) from patients with Barrett's esophagus, a COX-2-expressing HCA-7 colon cancer cell line (positive control), and a COX-2-deficient HCT-15 colon cancer cell line (negative control). The cells had been grown in the presence (+ lanes) or absence (-lanes) of the proinflammatory cytokines interleukin (IL)-1␤ (10 ng/mL) and tumor necrosis factor (TNF)-␣ (50 ng/mL) for 24 hours. Reverse transcriptionpolymerase chain reaction (PCR) was used to detect messenger RNA (mRNA) for COX-2 and ␤-globin (an internal control for the mRNA concentration and quality). PCR products were separated by electrophoresis through 1.2% agarose gels and visualized by staining with ethidium bromide. The left-most lane represents no mRNA control. B) COX-2 activity was determined by measuring prostaglandin E 2 (PGE 2 ) levels in the supernatants from cultures of primary BECC and primary BSFC grown in serum-free media in the presence (+ lanes) or absence (-lanes) of proinflammatory cytokines IL-1␤ (10 ng/mL) and TNF-␣ (50 ng/mL) for 24 hours. PGE 2 levels in culture supernatants from unstimulated COX-2-expressing HCA-7 colon cancer cells (positive control) and COX-2-deficient HCT-15 colon cancer cells (negative control) are shown for comparison. Bars represent the mean and upper 95% confidence interval. The left-most bar shows the PGE 2 level in the culture medium. Asterisks indicate that the PGE 2 level is below the detection limit of the enzyme immunoassay. PGE 2 levels were statistically significantly higher in culture supernatants from esophageal fibroblasts from patients with Barrett's esophagus than in those from Barrett's esophageal epithelial cells (P ‫ס‬ .002). PGE 2 levels were not statistically significantly higher in culture supernatants from IL-1␤-stimulated and TNF␣-stimulated Barrett's esophageal epithelial cells than in those from unstimulated epithelial cell cultures (P ‫ס‬ .044, Bonferroni adjustment ␣ ‫ס‬ 0.005) but were statistically significantly higher in those from IL-1␤-stimulated and TNF␣-stimulated esophageal fibroblasts (P<.001). P values were derived with a Bonferroni adjustment ␣ ‫ס‬ 0.005. ment with NS-398 statistically significantly decreased the percentage of proliferating Ki-67-positive Barrett's esophageal epithelial cells (P<.001). There was a dose-dependent relationship between NS-398 concentration and inhibition of proliferation (Fig. 2, A) . Compared with the proliferation of Barrett's esophageal epithelial cells treated with medium containing DMSO (11.6% proliferating cells; 95% CI ‫ס‬ 6.4% to 16.8%), the proliferation of Barrett's esophageal epithelial cells was inhibited when the cells were treated with 1 mol (8.5% proliferating cells; 95% CI ‫ס‬ 0.6% to 16.3%; P ‫ס‬ .038), 25 mol (8% proliferating cells; 95% CI ‫ס‬ 0.6% to 15.3%; P ‫ס‬ .018), or 50 mol NS-398 (5.5% proliferating cells; 95% CI ‫ס‬ 2.6% to 8.3%; P<.001, Bonferroni adjusted ␣ ‫ס‬ 0.0083).
To determine whether the inhibition in proliferation was associated with an increase in the percentage of apoptotic cells, we next assessed the percentage of TUNEL-positive cells in Barrett's esophageal epithelial cells 6 days after treatment with NS-398. Compared with Barrett's esophageal epithelial cells treated with DMSO (7.8%; 95% CI ‫ס‬ 5.6% to 9.8%), there was no statistically significant difference in the percentage of cells undergoing apoptosis among each of the treatment groups (7% [95% CI ‫ס‬ 5.3% to 8.6%], 8% [95% CI ‫ס‬ 4.9% to 11.0%], and 7.2% [95% CI ‫ס‬ 4.9% to 9.4%], for 1, 25, and 50 mol, respectively, P ‫ס‬ .874) (Fig. 2, B) .
We confirmed that treatment with NS-398 inhibited COX-2 activity by measuring PGE 2 levels. PGE 2 levels in culture supernatants of cells treated with 50 mol of NS-398 for 6 days declined from 0.9 ng/mg protein (95% CI ‫ס‬ 0 to 1.2 ng/mg) to below the detection level of the assay (0.075 ng/mL).
We next determined whether PGE 2 directly affected proliferation (Fig. 3) . A 48-hour treatment with 1 ng of exogenous PGE 2 increased the proliferation of Barrett's esophageal epithelial cells by 39.5% (95% CI ‫ס‬ 18.8% to 60%; P ‫ס‬ .001, 3 . Effect of the selective cyclooxygenase (COX)-2 inhibitor NS-398 and prostaglandin E 2 (PGE 2 ) on the proliferation of Barrett's esophageal epithelial cells. Primary Barrett's esophageal epithelial cell cultures were treated with NS-398 (50 mol), with PGE 2 (1 ng/mL) and NS-398 (50 mol), or with exogenous PGE 2 (1 ng/mL) for 48 hours. Control Barrett's esophageal epithelial cells were treated with dimethyl sulfoxide (DMSO) (final concentration 0.1%). After 48 hours, the cells were fixed and then sequentially stained with a mouse monoclonal antibody directed against Ki-67, a nuclear antigen expressed by cycling cells, and a fluorescein-conjugated anti-mouse secondary antibody. The number of fluorescent Ki-67-positive cells out of 300 cells was counted to determine the potentially proliferating fraction of Barrett's esophageal epithelial cells. Bars represent the mean of four cultures per group and upper 95% confidence interval of the percentage of Ki-67-positive cells relative to the DMSOtreated control group. Compared with control Barrett's esophageal epithelial cell cultures, proliferation was statistically significantly decreased in cultures treated with NS-398 (P ‫ס‬ .001), unchanged in those treated with NS-398 and PGE 2 (P ‫ס‬ .821), and statistically significantly increased in those treated with PGE 2 (P ‫ס‬ .001). P values were derived with a Bonferroni adjustment at the ␣ ‫ס‬ 0.0083 ‫ס(‬ 0.05/6) level.
Bonferroni adjusted
33% (95% CI ‫ס‬ 28% to 37%; P ‫ס‬ .001, Bonferroni adjusted ␣ ‫ס‬ 0.0083) relative to the control DMSO-treated cells. However, when Barrett's esophageal epithelial cells were treated concomitantly with PGE 2 and NS-398, there was no change in proliferation (P ‫ס‬ .821).
To confirm that the effects of NS-398 were specific for COX-2, we compared the effects of NS-398 on COX-2-expressing and COX-2-deficient colon cancer cell lines. Compared with DMSO-treated controls, treatment with NS-398 (50 mol for 6 days) decreased the proliferation of Barrett's esophageal epithelial cells by 55% (95% CI ‫ס‬ 47% to 64%; P<.001, Bonferroni adjusted ␣ ‫ס‬ 0.0083). Similarly, treatment with NS-398 (50 mol) inhibited the proliferation of HCA-7 cells by 52% (95% CI ‫ס‬ 19% to 85%; P<.001, Bonferroni adjusted ␣ ‫ס‬ 0.0083). However, treatment with NS-398 (50 mol) inhibited the proliferation of HCT-15 cells by only 6% (95% CI ‫ס‬ 0% to 20%; P ‫ס‬ .067, Bonferroni adjusted ␣ ‫ס‬ 0.0083).
Esophageal Fibroblasts Modulate COX-2 Activity of Barrett's Esophageal Epithelial Cells
Although the proinflammatory cytokines IL-1␤ and TNF-␣ had minimal direct effect on the COX-2 activity (PGE 2 levels) of Barrett's esophageal epithelial cells, we postulated that there could be a paracrine loop in Barrett's esophagus whereby these cytokines could activate stromal cells that in turn could stimulate the proliferation of the epithelial cells. We next examined whether esophageal fibroblasts could modulate the COX-2 activity of the Barrett's esophageal epithelial cells by a possible stromal-epithelial interaction. When Barrett's esophageal epithelial cells were treated with the conditioned medium from unstimulated fibroblasts, the PGE 2 level statistically significantly increased to 1.4 ng/mg protein (95% CI ‫ס‬ 0 to 2.8 ng/mg; P ‫ס‬ .004, Bonferroni adjusted ␣ ‫ס‬ 0.0083). When the Barrett's esophageal epithelial cells were treated with conditioned medium from 10 ng/mL IL-1␤-stimulated and 50 ng/mL TNF-␣-stimulated fibroblasts, the PGE 2 level underwent an even greater (and statistically significant) increase to 2.3 ng/mg protein (95% CI ‫ס‬ 0.8 to 3.7 ng/mg; P<.001, Bonferroni adjusted ␣ ‫ס‬ 0.0083) (Fig. 4) . This level may be an overestimate, however, because there was PGE 2 in the conditioned medium from the IL-1␤-stimulated and TNF-␣-stimulated fibroblasts (2.9 ng/mg protein; 95% CI ‫ס‬ 1.9 to 3.9 ng/mg protein). However, PGE 2 is very unstable in the conditioned medium, and the maximum PGE 2 concentration that could have persisted and transferred in the conditioned medium to the epithelial cells was 1.3 ng/mg protein. This assumption is based on our measurements of PGE 2 in conditioned media at room temperature; after 24 h, in the absence of any cells, the concentration of PGE 2 decreased by 55.2% (95% CI ‫ס‬ 46.5% to 64.3%). After correcting for this transferred amount, the IL-1␤-stimulated and TNF-␣-stimulated fibroblast-conditioned media still statistically significantly increased the PGE 2 level secreted from the Barrett's esophageal epithelial cells to 1 ng/mL protein (95% CI ‫ס‬ 0.3 to 1.6 ng/mL; P ‫ס‬ .002, Bonferroni adjusted ␣ ‫ס‬ 0.0083).
DISCUSSION
Barrett's esophagus is characterized by the replacement of normal squamous esophageal epithelium with a specialized columnar mucosa in response to chronic gastroesophageal reflux (1) . It is considered a premalignant condition that is associated with a 30-to 125-fold increased risk of esophageal adenocarcinoma relative to occurrence in the general population (23) . The incidence of esophageal adenocarcinoma is rapidly increasing among Caucasian males (2, 3) . The prognosis of esophageal adenocarcinoma is poor, with a 5-year survival rate of 13%-15% (24, 25) . Unfortunately, no medical therapy has been proven to attenuate the progression of Barrett's esophagus to esophageal cancer. Although mucosal ablative therapies have been proposed, their application is difficult and costly (26) . Therefore, developing a chemopreventive strategy for the management of Barrett's esophagus would be of great benefit.
Our findings indicate that COX-2 activity may be a potential target for the prevention of progression from premalignant Barrett's esophagus. Because Barrett's esophagus is associated with chronic inflammation and injury caused by the gastric contents during reflux, we focused on potential mediators of inflammation. COX-2 is an inducible isoform of cyclooxygenase, which is expressed in epithelial and stromal cells in response to injury, growth factors, tumor promoters, and cytokines (27) (28) (29) (30) . Animal studies (31) , in vitro cell culture experiments (32, 33) , and recent human studies (34, 35) all have shown that COX-2 is involved in colon carcinogenesis and that selective inhibition of COX-2 has antineoplastic effects. By contrast, Fig. 4 . Effect of proinflammatory cytokines and culture supernatants from esophageal fibroblasts on cyclooxygenase (COX)-2 activity (PGE 2 levels) of Barrett's esophageal epithelial cells. Primary Barrett's esophageal epithelial cell cultures, grown in serum-free media, were treated for 24 hours with 0.1% dimethyl sulfoxide, the proinflammatory cytokines interleukin (IL)-1␤ (10 ng/mL) and tumor necrosis factor (TNF)-␣ (50 ng/mL), conditioned medium (FCM) from unstimulated esophageal fibroblasts, or conditioned medium from stimulated esophageal fibroblasts (collected after 24 hours of treatment with IL-1␤ [10 ng/mL] and TNF-␣ [50 ng/mL]). COX-2 activity was assessed by measuring PGE 2 levels in the culture supernatants with a specific enzyme immunoassay. Bars represent the mean and upper 95% confidence interval of the PGE 2 level. Compared with PGE 2 levels from control cultures, those from Barrett's esophageal epithelial cell cultures treated with IL-1␤ and TNF-␣ did not statistically significantly change (P ‫ס‬ .044), whereas those from Barrett's esophageal epithelial cell cultures treated unstimulated fibroblast-conditioned medium (P ‫ס‬ .004) and stimulated fibroblast-conditioned medium (P<.001) did statistically significantly increase. P values were derived with a Bonferroni adjustment at the ␣ ‫ס‬ 0.0083 level.
there is limited information on the potential role of COX-2 in the development of esophageal adenocarcinoma from Barrett's esophagus. Wilson et al. (14) showed that COX-2 mRNA and protein expression are higher in Barrett's esophagus than in normal esophagus. Recently, Shrivini et al. (5) studied the expression of COX-2 in esophageal biopsy specimens by immunostaining and immunoblot analysis and demonstrated that expression of COX-2 is higher in Barrett's esophagus and esophageal adenocarcinoma than in normal esophagus and duodenum. Expression of COX-2 was substantially higher in dysplastic Barrett's esophagus and cancer than in nondysplastic Barrett's esophagus, whereas COX-1 expression was unchanged (5). COX-2 activity was not addressed in these studies (5, 6) , however, and it was not clear if the increased COX-2 expression had a functional relevance.
Our data suggest that COX-2 is not only expressed but is also functionally active in Barrett's esophagus because the inhibitor NS-398 statistically significantly inhibited the proliferation of Barrett's esophageal epithelial cells. At a concentration of 50 mol, NS-398 decreased the proliferation of Barrett's esophageal epithelial cells by more than 50% and completely inhibited COX-2 activity. NS-398 had comparable effects on the proliferation of the COX-2-expressing HCA-7 colon cancer cell line but had no effect on the proliferation of the COX-2-deficient HCT-15 colon cancer cell line. Moreover, we noted that PGE 2 , an end product of COX-2 activity, could stimulate proliferation of Barrett's esophageal epithelial cells and reverse the inhibitory effects of NS-398 on the proliferation of Barrett's esophageal epithelial cells. These findings suggest that COX-2 activity, as indicated by PGE 2 levels, has a functional relevance in the proliferation of Barrett's esophageal epithelial cells and may have a relevance to neoplastic progression in Barrett's epithelium. The inhibition of COX-2 activity may, therefore, have chemopreventive potential. Selective COX-2 inhibition did not increase apoptosis in Barrett's esophageal epithelial cells, which may be because proliferation rather than apoptosis is the dominant mechanism of neoplastic progression in the early stages of the Barrett's esophagus (36) .
Gastroesophageal reflux, which predisposes to Barrett's esophagus, is associated with injury and inflammation of the esophagus and induces proinflammatory cytokines such as IL-1␤ (16) . Proinflammatory cytokines can induce COX-2 (7) (8) (9) . Early during the development and progression of Barrett's esophagus, the expression of COX-2 is limited to the stromal cells (14) . The effect of proinflammatory cytokines on COX-2 activity in Barrett's esophageal epithelial and stromal cells and the interaction between stromal and epithelial cells have not been previously studied.
In this study, we noted that COX-2 activity in esophageal fibroblasts was statistically significantly higher than that in epithelial cells. Although the COX-2 activity of Barrett's esophageal epithelial cells was not directly affected by the presence of IL-1␤ and TNF-␣, COX-2 activity was markedly increased by the presence of supernatants from cultures of unstimulated and cytokine-stimulated esophageal fibroblasts. The esophageal fibroblasts may regulate COX-2 activity of Barrett's esophageal epithelial cells in response to proinflammatory cytokine stimulation and may provide a link between inflammation and carcinogenesis in Barrett's esophagus. The mechanism responsible for this regulation is unclear, but PGE 2 or growth factors, other than IL-1␤ and TNF-␣, released by fibroblasts in the conditioned media may play a role by increasing or stabilizing the transcription of the COX-2 mRNA.
In summary, COX-2 expression in Barrett's epithelium is of functional relevance because COX-2 activity is associated with increased proliferation of Barrett's esophageal epithelial cells. The selective COX-2 inhibitor NS-398 inhibited proliferation of Barrett's esophageal epithelial cells, without inducing apoptosis and may have a chemopreventive effect. Proinflammatory cytokine-stimulated stromal cells can induce COX-2 activity in Barrett's esophageal epithelial cells. The stromal-epithelial interactions could be an important link between inflammation and carcinogenesis.
